Modulation of the Th1/Th2 bias by an immunoglobulin histamine complex in the ovalbumin allergy mouse model.
Vaccination with the antiallergic drug Histaglobin is used to treat a broad range of human allergic diseases including bronchial asthma, allergic rhinitis, and atopic dermatitis. In order to further elucidate its functional activity, Histaglobin was investigated in an in vivo mouse allergy model. Mice were sensitized with ovalbumin either prior to or after Histaglobin treatment, and its antiallergic potential was evaluated. Ovalbumin-sensitized mice exhibited increased serum levels of IL-4, tumor necrosis factor alpha (TNF-alpha), and an increase of total and ovalbumin-specific IgE; total and ovalbumin-specific IgG levels were also elevated. Subsequent administration (therapeutic treatment) of Histaglobin resulted in a decrease of total and specific serum IgE levels; total and specific IgG1 serum levels were reduced by more than 50% and 45%, respectively; the mice displayed a down-regulation of IL-4 and TNF-alpha serum levels and showed increased levels of IFN-gamma and IgG2a. Mice pretreated with Histaglobin, prior to ovalbumin sensitization (prophylactic treatment), were found to be widely unresponsive to ovalbumin. They exhibited higher serum levels of IFN-gamma and IgG2a (total and specific) compared to saline-treated control mice. The inhibitory effects were still observed 1 month post-immunization. Our data, indicating a Histaglobin-induced modulation of the Th1/Th2 balance in favour of Th1, correspond with the well-known antiallergic activity of Histaglobin observed in patients.
Ayoub
M
M
Institut für Molekulare Medizin und Zellforschung, AG Tumorimmunologie/Vakzine, Universitätsklinikum Freiburg, Stefan-Meier-Str 8, D-79104 Freiburg, Germany.
Lallouette
P
P
Sütterlin
B W
BW
Bessler
W G
WG
Huber
M
M
Mittenbühler
K
K
D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D006632:Histamine / Q000627:therapeutic use*; D006967:Hypersensitivity / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D007073:Immunoglobulin E / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D005719:gamma-Globulins / Q000627:therapeutic use*
D018926:Anti-Allergic Agents; D004338:Drug Combinations; D014409:Tumor Necrosis Factor-alpha; D005719:gamma-Globulins; D015847:Interleukin-4; C002114:Histaglobin; D007073:Immunoglobulin E; D006632:Histamine; D010047:Ovalbumin